AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump administration "for obvious reasons."
By FierceBiotech
· Apr 18, 2026
· via FierceBiotech
Image: FierceBiotech
Tags
policyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
PolicyBriefing
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…
PolicyBriefing
Quest Diagnostics highlights growing pharma use of predictive analytics and lab results to improve launch targ…